StreetInsider.com News Articles

UBS Starts Tectonic Therapeutics Inc. (TECX) at Neutral

Mon, 12 Oct 2026 02:18:05 -0400

UBS analyst Alice Nettleton initiates coverage on Tectonic Therapeutics Inc. (NASDAQ: TECX) with a Neutral rating and a price target of $26.00.

The analyst comments: “We initiate coverage of Tectonic Therapeutic (TECX) with a Neutral rating and $26 PT. The key catalyst for TECX is the 1Q27 Phase 2 APEX readout for TX45, a long-acting relaxin, in Group 2 pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF). Based on our KOL checks and other research, we believe the study is likely to achieve its primary endpoint of pulmonary vascular resistance (PVR). However, six-minute walk distance (6MWD), which we

UBS Starts Tectonic Therapeutics Inc. (TECX) at Neutral

Mon, 12 Oct 2026 02:18:05 -0400

UBS analyst Alice Nettleton initiates coverage on Tectonic Therapeutics Inc. (NASDAQ: TECX) with a Neutral rating and a price target of $26.00.

Form 4 Tectonic Therapeutic, For: Sep 25 Filed by: Lochner Daniel

Fri, 02 Oct 2026 17:02:00 -0400

si-local-file:///var/storage/secattach/20261002/27143353.html

Form 4 Tectonic Therapeutic, For: Sep 25 Filed by: McNamara Peter

Fri, 02 Oct 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20261002/27143319.html

Form 4 Tectonic Therapeutic, For: Sep 25 Filed by: Ruddy Marcella K.

Fri, 02 Oct 2026 16:59:00 -0400

si-local-file:///var/storage/secattach/20261002/27143281.html

Form 4 Tectonic Therapeutic, For: Sep 25 Filed by: REICIN ALISE

Fri, 02 Oct 2026 16:58:00 -0400

si-local-file:///var/storage/secattach/20261002/27143265.html

Form 4 Tectonic Therapeutic, For: Sep 25 Filed by: Schwabish Marc

Fri, 02 Oct 2026 16:57:00 -0400

si-local-file:///var/storage/secattach/20261002/27143250.html

Stifel Reiterates Buy Rating on Tectonic Therapeutics Inc. (TECX)

Thu, 01 Oct 2026 02:32:36 -0400

Stifel analyst James Condulis reiterated a Buy rating and $75.00 price target on Tectonic Therapeutics Inc. (NASDAQ: TECX)

The analyst comments: “As part of Stifel's Virtual Cardiometabolic Forum, we hosted CEO Alise Reicin and CFO Daniel Lochner to discuss relaxin and TX45's positioning ahead of APEX (early-1Q27)--we also briefly recapped yesterday's HHT data. A lot has happened with relaxin/Group 2 broadly--and given several setbacks, there's healthy skepticism ahead of APEX. That said, discussed below, there are key learnings where--alongside the ph1b--management's confidence has actually increased as over-time: safety is arguably de-risked, we've seen some evidence of durable hemodynamic benefits, and it's

Form 144 Tectonic Therapeutic, Filed by: McNamara Peter

Wed, 30 Sep 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260930/27128912.html

Oppenheimer Reiterates Outperform Rating on Tectonic Therapeutics Inc. (TECX)

Wed, 30 Sep 2026 05:59:44 -0400

Oppenheimer analyst Leland Gershell reiterated an Outperform rating and $80.00 price target on Tectonic Therapeutics Inc. (NASDAQ: TECX).

The analyst comments "We view the first clinical look at TX2100 as a positive step for TECX's hereditary hemorrhagic telangiectasia (HHT) program. The healthy volunteer data show just what we wanted to see: single doses of IV/SC TX2100 were well-tolerated across all six cohorts, PK results confirm high affinity target engagement, and, together with animal model data, suggest an exposure range for upcoming investigation. Two studies in HHT patients, an open-label Phase 1b and a placebo-controlled Phase 2, are slated to begin by

TD Cowen Reiterates Buy Rating on Tectonic Therapeutics Inc. (TECX)

Wed, 30 Sep 2026 02:39:53 -0400

TD Cowen analyst Tyler Van Buren reiterated a Buy rating and {REMOVEPT} price target on Tectonic Therapeutics Inc. (NASDAQ: TECX)

The analyst comments: “Tectonic reported preliminary Phase Ia PK and safety data of TX2100 for HHT. Detailed results will be presented at the CureHHT conference in mid-October, but preliminary data in HVs showed a favorable safety profile and PK characteristics supporting weekly or every-other week SC dosing. Part b is dosing and TECX expects to initiate a Phase II trial in moderate-to severe HHT patients in early 2027.

Preliminary Phase Ia TX2100 Demonstrates A Favorable PK And Tolerability Profile; Full Data Expected

Form 8-K Tectonic Therapeutic, For: Sep 29

Tue, 29 Sep 2026 17:19:00 -0400

si-local-file:///var/storage/secattach/20260929/27123456.html

Tectonic Therapeutic reports positive Phase 1a safety data for TX2100

Tue, 29 Sep 2026 08:00:54 -0400

Tectonic Therapeutic, Inc. (NASDAQ: TECX) announced favorable topline results from a Phase 1a clinical trial of TX2100, an investigational antibody targeting the APJ receptor, being developed as a treatment for Hereditary Hemorrhagic Telangiectasia (HHT), a rare inherited vascular disorder with no currently approved therapies.

The Phase 1a trial, a randomized, double-blind, placebo-controlled, single ascending dose study conducted at CMAX Clinical Research in Adelaide, South Australia, enrolled 48 healthy adult volunteers across six dose cohorts. Single ascending doses administered intravenously and subcutaneously were reported as generally safe and well-tolerated. Treatment-emergent adverse events were mild or moderate and transient, with no deaths, serious

Tectonic Therapeutic Announces Favorable Phase 1 Safety, Tolerability and PK Results for TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT)

Tue, 29 Sep 2026 08:00:00 -0400

U.S. FDA has granted Fast Track designation for TX2100 in HHT and cleared the Investigational New Drug (IND) application for the TX2100 Phase 1b clinical trial in HHT patients in the U.S.
TX2100 Phase 1a clinical trial topline results demonstrated single ascending doses of TX2100 were generally safe and well-tolerated in healthy adult volunteers
Company plans to initiate an open-label TX2100 Phase 1b clinical trial in patients with hematologic-support dependent HHT by year-end 2026, and initiate a Phase 2 clinical trial in parallel in patients with moderate-to-severe HHT in early 2027

WATERTOWN, Mass., Sept.

Tectonic Therapeutic Announces Favorable Phase 1 Safety, Tolerability and PK Results for TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT)

Tue, 29 Sep 2026 08:00:00 -0400

U.S. FDA has granted Fast Track designation for TX2100 in HHT and cleared the Investigational New Drug (IND) application for the TX2100 Phase 1b clinical trial in HHT patients in the U.S.
TX2100 Phase 1a clinical trial topline results demonstrated single ascending doses of TX2100 were generally safe and well-tolerated in healthy adult volunteers
Company plans to initiate an open-label TX2100 Phase 1b clinical trial in patients with hematologic-support dependent HHT by year-end 2026, and initiate a Phase 2 clinical trial in parallel in patients with moderate-to-severe HHT in early 2027

WATERTOWN, Mass., Sept.

Tectonic Therapeutic to Participate in the Morgan Stanley Global Healthcare Conference

Thu, 03 Sep 2026 08:00:00 -0400

WATERTOWN, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that Alise Reicin, MD, President and Chief Executive Officer, will participate in a fireside chat at the upcoming Morgan Stanley 24th Annual Global Healthcare Conference.

Morgan Stanley 24th Annual Global Healthcare Conference

Date:

September 14, 2026

Time:

5:35 PM ET

Location:

New York, NY

Format:

Fireside Chat

Presenter:

Alise Reicin,

Tectonic Therapeutic to Participate in the Morgan Stanley Global Healthcare Conference

Thu, 03 Sep 2026 08:00:00 -0400

Morgan Stanley 24th Annual Global Healthcare Conference

Date:	September 14, 2026
Time:	5:35 PM ET
Location:	New York, NY
Format:	Fireside Chat
Presenter:	Alise Reicin, Oppenheimer on Tectonic Therapeutics Inc. (TECX): 'Reaction Provides Opportunity' Tue, 01 Sep 2026 06:04:52 -0400 Oppenheimer analyst Leland Gershell reiterated an Outperform rating and $80.00 price target on Tectonic Therapeutics Inc. (NASDAQ: TECX). The analyst comments "TECX shares are under pressure following AZN's LUMINARA Phase 2b readout at ESC—yet the data add support to our favorable outlook on TX45, and we would take advantage of the weakness. LUMINARA provides the first evidence of efficacy with chronic relaxin agonism in heart failure, alongside clear target engagement and reassuring safety. Following our discussion with management, we also think the dose response supports TECX's view that appropriate relaxin exposure is critical, and emphasize that the study was not designed Stifel: 'we continue to think there's a credible case TECX/TX45 offers the best test of the relaxin hypothesis' Mon, 31 Aug 2026 10:58:39 -0400 Stifel: 'we continue to think there's a credible case TECX/TX45 offers the best test of the relaxin hypothesis'. The analyst comments "We thought the detailed AZD5462 data were nuanced--but interesting. We also touched base with management on implications where ultimately we do think there are some positive (albeit complicated/nuanced) takeaways for APEX/relaxin broadly. More notably--this is another encouraging datapoint re:safety. But also this is arguably the first signals of efficacy w/relaxin in a chronicHF setting where we see durable hemodynamic changes (no tachyphylaxis; and some signals on NTproBNP, LVEF). Now to be clear, the overall dataset is definitely messy and the Form 144 Tectonic Therapeutic, Filed by: MCGUIRE TERRANCE Thu, 27 Aug 2026 17:20:00 -0400 si-local-file:///var/storage/secattach/20260827/26991263.html Form 144 Tectonic Therapeutic, Filed by: MCGUIRE TERRANCE Thu, 27 Aug 2026 17:20:00 -0400 si-local-file:///var/storage/secattach/20260827/26991263.html Form 4 Tectonic Therapeutic, For: Aug 25 Filed by: McNamara Peter Wed, 26 Aug 2026 16:31:00 -0400 si-local-file:///var/storage/secattach/20260826/26982261.html Form 4 Tectonic Therapeutic, For: Aug 25 Filed by: McNamara Peter Wed, 26 Aug 2026 16:31:00 -0400 si-local-file:///var/storage/secattach/20260826/26982261.html Form 144 Tectonic Therapeutic, Filed by: MCGUIRE TERRANCE Fri, 21 Aug 2026 17:58:00 -0400 si-local-file:///var/storage/secattach/20260821/26962628.html Form 144 Tectonic Therapeutic, Filed by: MCGUIRE TERRANCE Fri, 21 Aug 2026 17:58:00 -0400 si-local-file:///var/storage/secattach/20260821/26962628.html

StreetInsider.com News Articles

UBS Starts Tectonic Therapeutics Inc. (TECX) at Neutral

UBS Starts Tectonic Therapeutics Inc. (TECX) at Neutral

Form 4 Tectonic Therapeutic, For: Sep 25 Filed by: Lochner Daniel

Form 4 Tectonic Therapeutic, For: Sep 25 Filed by: McNamara Peter

Form 4 Tectonic Therapeutic, For: Sep 25 Filed by: Ruddy Marcella K.

Form 4 Tectonic Therapeutic, For: Sep 25 Filed by: REICIN ALISE

Form 4 Tectonic Therapeutic, For: Sep 25 Filed by: Schwabish Marc

Stifel Reiterates Buy Rating on Tectonic Therapeutics Inc. (TECX)

Form 144 Tectonic Therapeutic, Filed by: McNamara Peter

Oppenheimer Reiterates Outperform Rating on Tectonic Therapeutics Inc. (TECX)

TD Cowen Reiterates Buy Rating on Tectonic Therapeutics Inc. (TECX)

Form 8-K Tectonic Therapeutic, For: Sep 29

Tectonic Therapeutic reports positive Phase 1a safety data for TX2100

Tectonic Therapeutic Announces Favorable Phase 1 Safety, Tolerability and PK Results for TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT)

Tectonic Therapeutic Announces Favorable Phase 1 Safety, Tolerability and PK Results for TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT)

Tectonic Therapeutic to Participate in the Morgan Stanley Global Healthcare Conference

Tectonic Therapeutic to Participate in the Morgan Stanley Global Healthcare Conference

Oppenheimer on Tectonic Therapeutics Inc. (TECX): 'Reaction Provides Opportunity'

Stifel: 'we continue to think there's a credible case TECX/TX45 offers the best test of the relaxin hypothesis'

Form 144 Tectonic Therapeutic, Filed by: MCGUIRE TERRANCE

Form 144 Tectonic Therapeutic, Filed by: MCGUIRE TERRANCE

Form 4 Tectonic Therapeutic, For: Aug 25 Filed by: McNamara Peter

Form 4 Tectonic Therapeutic, For: Aug 25 Filed by: McNamara Peter

Form 144 Tectonic Therapeutic, Filed by: MCGUIRE TERRANCE

Form 144 Tectonic Therapeutic, Filed by: MCGUIRE TERRANCE